Co-creation is paramount to our work. HCP Marketing Lead Jenny L. Reid and Clinical Scientist Stéphanie Dincq discuss how their teams prepared for our recent approval in #CIDP treatment, from designing the ADHERE trial, to connecting with patients and HCPs. #TogetherWeDiscover
argenx
Biotechnology Research
Boston, MA 63,632 followers
United in our commitment to improve the lives of patients
About us
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
- Website
-
http://www.argenx.com
External link for argenx
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- Oncology, Autoimmune diseases, Rare Diseases, Antibody based medicines, Immunotherapy, Myasthenia Gravis, Immunology, Pemphigus Vulgaris, Immune Thrombocytopenia, Acute Myeloid Leukemia , high-risk myelodysplastic syndromes, and chronic inflammatory demyelinating polyneuropathy
Locations
-
Primary
33 Arch Street
Suite 3201
Boston, MA 02110, US
-
Technologiepark 30
Ghent, 9052, BE
-
3-19-23 Minami-Azabu, Minato-KU
Tokyo , 106-0047, JP
Employees at argenx
Updates
-
At the European Academy of Neurology Congress, we're sharing how our collaborations with disease biology experts have helped us develop and deliver novel, targeted therapies for autoimmune patients in need. Learn more about our immunology research: https://bit.ly/3VPEhwu #TogetherWeDiscover #EAN2024
-
We are proud of our argonauts’ dedication to delivering innovative treatments to patients in need. Our recent FDA approval in chronic inflammatory demyelinating polyneuropathy (CIDP) is a testament to the value of collaborations with disease biology experts and the autoimmune patient community. Discover more about our work to advance #CIDP treatment: https://bit.ly/4cFeVZb #TogetherWeDiscover
-
At this year’s Peripheral Nerve Society Annual Meeting, we presented insights on the immune mechanisms in multifocal motor neuropathy (MMN). Learn more about our immunology research: bit.ly/3VJjs68 #TogetherWeDiscover #PNS2024
-
-
At argenx, we are committed to advancing the treatment landscape for rare, autoimmune diseases, like chronic inflammatory demyelinating polyneuropathy (CIDP). With our recent FDA approval, we are thrilled to provide the #CIDP community with a new, innovative treatment option. Learn more: bit.ly/4eIWlkT #TogetherWeDiscover
CIDP Treatment
-
For people living with autoimmune conditions, the disease burden remains high. We’re eager to share how our targeted solutions are addressing unmet autoimmune patient needs at the European Academy of Neurology Congress. Discover more about our commitment to this community: bit.ly/4eBL0Tu #TogetherWeDiscover #EAN2024
-
Today we announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks a key advancement in the understanding of rare, autoimmune diseases, and we are proud to deliver a new, innovative option for the #CIDP community. #TogetherWeDiscover Learn more: https://bit.ly/45D76Rl
-
As a Clinical Scientist, Bianca Balbino (She/Her) collaborates with disease area experts to better understand treatment gaps and opportunities to bring innovative immunology solutions to patient communities. Discover opportunities to join argenx in transforming patient lives through innovation: https://bit.ly/3yXimM9 #TogetherWeDiscover #BiotechCareers
Your Future Fridays
-
This month is both #PrideMonth and #MGAwarenessMonth! We’re excited to partner with the Myasthenia Gravis Association for their MG Pride Panel this week, where we’ll hear from members of the LGBTQ+ community living with MG.
In honor of Pride Month, the Myasthenia Gravis Association in partnership with argenx is excited to host a special panel event celebrating the intersection of the LGBTQ+ community and those living with myasthenia gravis. This event aims to highlight the unique challenges and triumphs of LGBTQ+ individuals managing MG, while fostering a supportive and inclusive environment. @mgunited_official Join us Tomorrow the 11th from 6-7pm via zoom! Register here: https://lnkd.in/eRVEVzv5 #careaboutrare #rarekc #mgstrong #ihaveheardofmg #mgawareness #neuromuscular #autoimmune #myastheniagravis #worldwithoutmg #mga5k #mgatriplecrownshowdown #mgarun #missouricures
-
-
We are proud to share that argenx has received the 2024 Prix Galien UK Award for “Best Product for Orphan Disease” for our innovative work in advancing treatment options for myasthenia gravis (MG). David Knechtel, General Manager, argenx UK shared, “It’s an honour and privilege to be recognized for this important innovation for patients with MG.” Learn more about our commitment to the MG community: https://bit.ly/3yMjlii #TogetherWeDiscover
-